|
Getting your Trinity Audio player ready...
|
Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, announced a new collaboration with Anthropic on September 16 that will bring Claude’s frontier AI models, including the specialized Claude Science platform, directly into the company’s drug discovery and development workflows. The deal marks the latest in a string of technology partnerships Novo has struck throughout 2026 as it works to reposition itself as what its leadership describes as the world’s most AI-driven healthcare company.
Under the arrangement, Novo Nordisk’s scientists and computational teams will work with Anthropic to identify specific drug discovery challenges within the company’s research pipeline, then jointly develop targeted AI tools aimed at those scientific problems and workflows, with a particular focus on supporting biological reasoning. The company will begin by testing Claude Science in selected research and development workflows, concentrating on the scientific problems where the two companies expect their combined expertise to deliver the greatest impact, rather than rolling the technology out uniformly across every stage of drug development at once.
Novo Nordisk CEO Mike Doustdar framed the partnership as an extension of the company’s broader AI strategy rather than a standalone initiative, saying joining forces with Anthropic would help supercharge the company’s R&D organization in pursuit of new treatments for people living with chronic diseases. He added that AI carries the potential to increase R&D productivity and compress the path from early research to a marketed product, while also opening entirely new scientific opportunities that aid reasoning and understanding of human biology and drug mechanisms.
Anthropic CEO Dario Amodei described the partnership in terms of compounding capability gains rather than a single incremental improvement, saying AI’s growing capability carries the potential to compress a century’s worth of biological and medical breakthroughs into a single decade. He said giving leading researchers access to safe, capable and trusted frontier models could shorten research timelines, improve outcomes, and help discover medicines and treatments that meaningfully improve human life.
This is not Novo’s first experience working with Claude. The company had already been using Anthropic’s models to automate trial report generation, a use case that reportedly compressed patient documentation timelines from what previously took months down to minutes. That earlier, narrower deployment appears to have functioned as a proof point ahead of the broader research collaboration now being announced, which helps explain why this expansion reads more as a scaling up of an existing working relationship than a first-time pilot between the two companies.
Novo Nordisk has said the collaboration includes data-governance controls and human oversight specifically intended to ensure the technology gets used in line with the company’s ethical and compliance standards, a detail that matters given how tightly regulated pharmaceutical research and development remains, and how much scrutiny AI-assisted drug discovery tools are likely to face from regulators as their use becomes more widespread across the industry.
The Anthropic deal is one piece of a considerably larger AI strategy Novo Nordisk has been assembling throughout the year. The company partnered with OpenAI in April 2026 for enterprise-wide AI integration spanning drug discovery, manufacturing and commercial operations, and separately named Amazon Web Services its preferred strategic cloud and AI infrastructure partner in August 2026. Layering an Anthropic partnership on top of those existing relationships suggests Novo is deliberately working with multiple frontier AI providers rather than consolidating around a single vendor, an approach that gives the company flexibility to apply different models to different research problems depending on which performs best for a given task.
For Anthropic, the Novo Nordisk deal extends a life sciences strategy that has been building steadily over the past several months. In May 2026, the company announced a collaboration with Bristol Myers Squibb that deployed Claude across more than 30,000 employees spanning research, clinical development, manufacturing, commercial and corporate functions, giving Anthropic an earlier, large-scale reference point within the pharmaceutical industry. The company also reportedly acquired stealth drug-discovery biotech Coefficient Bio for approximately $400 million in April 2026, a move that suggests Anthropic has been building out dedicated scientific and biological expertise internally rather than relying solely on partnerships to establish credibility in the life sciences space.
That combination of an internal biotech acquisition and now two marquee pharmaceutical partnerships positions Anthropic to compete more directly with OpenAI and other AI labs for a share of the rapidly growing market for AI-assisted drug discovery tools, a sector where pharmaceutical companies are increasingly willing to spend heavily given the enormous cost and multi-year timelines traditionally associated with bringing a new drug from early research through clinical trials to market approval. Neither Novo Nordisk nor Anthropic disclosed financial terms for the collaboration.
The broader industry context makes clear why deals like this one are becoming increasingly common rather than remaining a novelty. Drugmakers across the pharmaceutical sector are turning to artificial intelligence at an accelerating pace specifically to speed up R&D timelines and cut costs across their development pipelines, a shift driven by mounting pressure to bring new treatments to market faster while managing the enormous expense involved in traditional drug discovery processes. Novo Nordisk, which develops treatments for chronic conditions including diabetes and obesity and employs more than 67,000 people globally, has positioned this latest collaboration as directly tied to its stated mission of preventing disease and expanding access to treatment, framing the Anthropic partnership as a tool for advancing that goal rather than simply an efficiency exercise.
Whether the collaboration produces measurable acceleration in Novo’s actual drug pipeline, rather than remaining confined to internal workflow improvements and software development support, will likely become clearer as the two companies begin identifying and tackling specific scientific problems together over the coming months. Continuing coverage of how AI is reshaping pharmaceutical research and drug discovery is available on Business Tech. Additional detail on the partnership is available through Anthropic’s official announcement, and further information on Novo Nordisk’s broader AI strategy can be found through the company’s official site.
